logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9956294 B1

PDFFull Text
Date of Patent:
May. 01, 2018

Filed:

Jan. 21, 2014

Targeted sensitization of non-del(5q) malignant cells

Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventors:

Alan List, Tampa, FL (US);

Sheng Wei, Tampa, FL (US);

Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Attorney:

Meunier Carlin & Curfman LLC

Primary Examiner:

Jennifer Pitrak McDonald

Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 47/48 (2006.01); A61K 31/711 (2006.01); A61K 38/00 (2006.01); A61K 31/454 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48092 (2013.01); A61K 31/454 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); C12N 15/1137 (2013.01); C12Y 301/03016 (2013.01); C12Y 301/03048 (2013.01); C12N 2310/14 (2013.01);
Abstract

Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.

Find Patent Forward Citations

List, Alan. (2018). Targeted sensitization of non-del(5q) malignant cells (U.S. Patent No. 9956294). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9956294

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…